InflaRx NV
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
/ 
Others were interested in
Frequently asked questions
To buy InflaRx NV stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for InflaRx NV by name or ticker, choose the number of shares, and place your order.
The ticker symbol for InflaRx NV is IFRX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
InflaRx NV has its primary listing on NASDAQ. You can trade InflaRx NV with a Saxo account, alongside thousands of other stocks worldwide.
Yes, InflaRx NV is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include InflaRx NV as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like InflaRx NV.